Modality
Gene Editing
MOA
VEGFi
Target
Aβ
Pathway
PI3K/AKT
MesoBCCCholangiocarcinoma
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
Aug 2019
→ Aug 2031
Phase 2Current
NCT03126755
2,123 pts·Meso
2019-08→2031-08·Terminated
NCT06688865
2,774 pts·Meso
2024-03→2026-04·Recruiting
4,897 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-04-033d awayPh2 Data· Meso
2026-09-025mo awayEnrollment Complete· Cholangiocarcinoma
2031-08-205.4y awayPh2 Data· Meso
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Termina…
P2
Recruit…
Catalysts
Ph2 Data
2026-04-03 · 3d away
Meso
Enrollment Complete
2026-09-02 · 5mo away
Cholangiocarcinoma
Ph2 Data
2031-08-20 · 5.4y away
Meso
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03126755 | Phase 2 | Meso | Terminated | 2123 | EFS |
| NCT06688865 | Phase 2 | Meso | Recruiting | 2774 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK |